Study of Pegilodecakin (LY3500518) With Nivolumab Compared to Nivolumab Alone Second-line Tx in Participants With Metastatic Non-Small Cell Lung Cancer

Clinical Research Alliance, Inc., New Hyde Park

Winthrop University Hospital, Mineola

Stony Brook University Medical Center, Stony Brook

Broome Oncology LLC, Johnson City

Maryland Oncology Hematology, P.A., Columbia

MedStar Health Research Institute, Baltimore

Frederick Memorial Hospital, Frederick

Fairfax Northern Virginia Hematology Oncology, PC, Fairfax

Oncology and Hematology Associates of Southwest Virginia Inc, Roanoke

Charleston Hematology Oncology Associates, Charleston

John B. Amos Cancer Center, Columbus

Hattiesburg Clinic, Hattiesburg

Baptist Health Medical Group, Lexington

Gabrail Cancer Center, Canton

Christ Hospital, Cincinnati

Sparrow Health System, Lansing

Covenant Clinic, Waterloo

Texas Oncology - Dallas Presbyterian Hospital, Dallas

Texas Oncology-Baylor Charles A. Sammons Cancer Center, Dallas

Texas Oncology - Tyler, Tyler

Texas Oncology-Memorial City, Houston

Millennium Oncology, Houston

US Oncology, The Woodlands

Mamie McFaddin Ward Cancer Center, Beaumont

Joe Arrington Cancer Center, Lubbock

Texas Oncology - Midland Allison Cancer Center, Midland

Rocky Mountain Cancer Center, Lone Tree

Arizona Oncology Associates, P.C., Tempe

Glendale Adventist Medical Center, Los Angeles

Beverly Hills Cancer Center, Beverly Hills

The Oncology Institute of Hope and Innovation, Whittier

Redwood Regional Oncology Center, Santa Rosa

MultiCare Regional Cancer Center - Auburn, Tacoma

The Valley Hospital - Luckow Pavilion, Westwood

University of Toledo Medical Center, Toledo